Publications
Detailed Information
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Tae-Min | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Lee, Sung Sook | - |
dc.contributor.author | Shin, Seong Hoon | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Park, Keon Uk | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Yun, Hwan Jung | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T11:08:22Z | - |
dc.date.available | 2020-04-27T11:08:22Z | - |
dc.date.created | 2018-09-05 | - |
dc.date.issued | 2017-04 | - |
dc.identifier.citation | Cancer Research and Treatment, Vol.49 No.2, pp.416-422 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.other | 50794 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165258 | - |
dc.description.abstract | Purpose The objective of this multicenter phase II study was to evaluate the efficacy and safety of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer. Materials and Methods Patients were treated with irinotecan 65 mg/m(2) and cisplatin 30 mg/m(2) on days 1 and 8 of each 21-day treatment cycle. The primary endpoint was response rate, and secondary endpoints were survival, duration of response, initial metabolic response rate, and toxicity. Results A total of 27 patients with squamous cell histology were enrolled in the study. The median age of the patients was 61 years. The objective response rate of the 20 patients in the per protocol group was 30.0% (90% confidence interval [Cl], 13.2 to 46.9). The median follow-up duration was 10.0 months, and the median progression-free survival and overall survival were 4.5 months (95% CI, 1.6 to 6.2) and 8.8 months (95% CI, 4.7 to 10.5), respectively. Four of 13 patients (30.8%) evaluated showed initial metabolic response. The median duration of response for partial responders was 5.0 months (range, 3.4 to 8.0 months). The following grade 3/4 treatment-related hematologic toxicities were reported: neutropenia (40.7%), anaemia (22.2%), and thrombocytopenia (7.4%). Two patients experienced febrile neutropenia. The most common grade 3/4 non-hematologic toxicities were asthenia (14.8%) and diarrhoea (11.1%). Conclusion Irinotecan and cisplatin combination chemotherapy showed modest anti-tumour activity and manageable toxicity for patients with metastatic, unresectable esophageal cancer. | - |
dc.language | 영어 | - |
dc.publisher | 대한암학회 | - |
dc.title | Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 이종석 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.identifier.doi | 10.4143/crt.2016.121 | - |
dc.citation.journaltitle | Cancer Research and Treatment | - |
dc.identifier.wosid | 000399355700014 | - |
dc.identifier.scopusid | 2-s2.0-85017375313 | - |
dc.citation.endpage | 422 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 416 | - |
dc.citation.volume | 49 | - |
dc.identifier.sci | 000399355700014 | - |
dc.identifier.kciid | ART002214554 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | SQUAMOUS-CELL CARCINOMA | - |
dc.subject.keywordPlus | NEOADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PATHOLOGICAL RESPONSE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | STATISTICS | - |
dc.subject.keywordPlus | PREDICTION | - |
dc.subject.keywordPlus | PET/CT | - |
dc.subject.keywordAuthor | Esophageal neoplasms | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | Phase II clinical trial | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.